Citations

Showing 10 of 108104 citations.

The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain
Tang, Hoi Ki Karen, Fung, Chi Yeung, Kumar, Shaji , Siu, Lisa L. P. , Ip, Ho Wan Alvin, Yip, Sze Fai, Lau, Ka Ngai Harry, Lau, Chi Kuen, Leung, Kwan Hung, Kho, B C S, Wong, Howard, Ngai, Cheong , Hwang, Yu Yan, Sim, Joycelyn, Kumar, Shaji K , Chim, Chor Sang , Morgan, Gareth J. , Lee, Harold , Wong, Howard, Hwang, Yu‐Yan , Kwong, Yok‐Lam , Chim, Chor Sang

Mayo Clinic

Therapeutic Advances in Hematology | April 18, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/20406207221082043 | PMID 35465644 Get It

Introduction: Bortezomib has been reported to favourably impact the outcomes of t(4;14) and del(17p) in multiple myeloma (MM), but its impact on gain 1q (+1q) is unknown. Methods: To address this, 250 patients treated with bortezomib-based induction were analysed. All myeloma samples had fluorescence in situ hybridization (FISH) performed on CD138-sorted bone marrow aspirate, and plasma cells were analysed using DNA probes specific for the following chromosomal aberrations: del(13q14), del(17p), t(14;16), t(4;14), and +1q. Presence of +1q was defined as the presence of at least three copies of 1q21 at the cut off level of 20% of bone marrow plasma cells. Results: +1q identified in 167 (66.8%) and associated with t(4;14) and high lactate dehydrogenase (LDH). +1q was not associated with response rate but shorter event-free survival (EFS) (median EFS 35 vs 55 months, p = 0.05) and overall survival (OS) (median OS 74 vs 168 months, p = 0.00025). Copy number and clone size did not impact survival. Multivariate analysis showed +1q was an independent adverse factor for OS together with International Staging System (ISS)3, high LDH, del(17p) and t(4;14). When a risk score of 1 was assigned to each independent adverse factor, OS was shortened incrementally by a risk score from 0 to 4. Post-relapse/progression survival was inferior in those with +1q (median 60 vs 118 months, p = 0.000316). Autologous stem cell transplantation (ASCT) improved OS for those with +1q (median OS 96 vs 49 months, p = 0.000069). Conclusion: +1q is an adverse factor for OS in MM uniformly treated with bortezomib-based induction but was partially mitigated by ASCT. A risk scoring system comprising +1q, LDH, high-risk FISH, and ISS is a potential tool for risk stratification in MM.
Mannose treatment improves immune deficiency in mannose phosphate isomerase–congenital disorder of glycosylation: case report and review of literature
Graef, Diederik De , Mousa, Jehan , Waberski, Marta Biderman, De Graef, Diederik , Morava, Éva

Mayo Clinic

Therapeutic Advances in Rare Disease | April 18, 2022 | Volume: 3 | Issue: No issue available | Pages: No page available

10.1177/26330040221091283 | PMID 37180423 Get It

Mannose phosphate isomerase–congenital disorder of glycosylation (MPI-CDG) is a CDG presenting with a clinically recognizable presentation, including early hypoglycemia, coagulation defects, and gastrointestinal and hepatic symptoms. We report on a female patient with biallelic pathogenic mutations in the MPI gene who presented with recurrent respiratory infections and abnormal IgM levels, but none of the classic symptoms associated with MPI-CDG. Oral mannose therapy led to a fast improvement in serum IgM levels and transferrin glycosylation in our patient. The patient did not experience severe infections after the initiation of treatment. We also reviewed the immune phenotype in patients so far reported with MPI-CDG.
Survival and associated predictors for patients with pineoblastoma or pineal parenchymal tumors of intermediate differentiation older than 3 years: Insights from the National Cancer Database
Kerezoudis, Panagiotis , Yolcu, Yagiz U. , Laack, Nadia N., Ruff, Michael W. , Khatua, Soumen , Kizilbash, Sani H. , Yolcu, Yagiz Ugur, Kizilbash, Sani H , Daniels, David J. , Burns, Terry C.

Mayo Clinic

Neuro-Oncology Advances | April 17, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac057 | PMID 35611271 Get It

Abstract Background The management of pineal parenchymal tumors remains controversial. Methods The 2004-2017 National Cancer Database was queried for cases (age >3 years) with histologically confirmed pineal parenchymal tumors of intermediate differentiation (PPTID, n = 90) or pineoblastoma (n = 106). Results Within the PPTID group, median age was 41 years; 49% were males. Five- and 10-year survival were 83% and 78%, respectively. Adjuvant radiation and chemotherapy were administered in 64% and 17% patients, respectively. The effect of radiation with or without chemotherapy (HR 1.15, P = .81, and HR 1.31, P = .72, respectively), and extent of resection (HR = 1.07, P = .93) was not significant. Within the pineoblastoma group, median age was 25 years; 51% were males. Five- and 10-year survival were 66% and 42%, respectively. Adjuvant radiation and chemotherapy were administered in 72% and 51%, respectively. In multivariable analysis, patients with pineoblastoma who received both radiation and chemotherapy (n = 39) had significantly lower hazard of death (HR 0.35, 95% CI 0.14-0.85, P = .02) compared to those who received radiation alone (n = 20) or no adjuvant treatment (n = 19). Finally, females in the pineoblastoma group were found to have a lower hazard of death compared to males (HR 0.24, 95% CI 0.10-0.58, P = .001); this comparison trended toward statistical significance in the PPTID subgroup (HR 0.40, 95% CI 0.14-1.08, P = .07). Conclusions Survival rates were higher in patients with PPTID vs patients with pineoblastoma. Adjuvant chemoradiation was associated with improved survival in pineoblastoma and females had lower hazards of death. Further research should identify specific patient profiles and molecular subgroups more likely to benefit from multimodality therapy.
Perioperative chemotherapy for resectable colorectal liver metastases: Analysis from the Colorectal Operative Liver Metastases International Collaborative (COLOMIC)
Gawdi, Rohin , Moaven, Omeed , Piccolo, Nico R. Del, Corvera, Carlos U. , Wisneski, Andrew D. , Cha, Charles , Russell, Greg, Zarandi, Nima Pourhabibi , Dourado, Justin , Shen, Perry , Moaven, Omeed , Del Piccolo, Nico R, Valenzuela, Cristian D. , Stauffer, John , Cheung, Tan To

Mayo Clinic

Journal of Surgical Oncology | April 16, 2022 | Volume: 126 | Issue: 2 | Pages: 339-347

10.1002/jso.26893 | PMID 35429409 Get It

AbstractBackgroundChemotherapy has been increasingly combined with surgery as multimodality treatment for resectable colorectal‐liver metastases (CLM). There is paucity of clinical data addressing optimal timing of chemotherapy relative to surgery. We examined outcomes of patients undergoing hepatectomy for resectable CLM.MethodsSeven hundred and eighteen patients treated with hepatectomy for CLM were analyzed from five hepatobiliary institutions between 2000 and 2018. Overall survival (OS) was measured from time of hepatectomy for patients receiving: surgery alone, neoadjuvant, adjuvant, and neoadjuvant‐plus‐adjuvant (perioperative) chemotherapy. Kaplan–Meier analysis was performed to detect differences in OS between treatment groups. Single‐ and multi‐variable analysis with Cox proportional hazards were run for OS between groups.ResultsOne hundred and thirty‐seven patients (19.08%) received surgery, 104 (14.48%) received neoadjuvant‐only, 214 (29.81%) received adjuvant‐only, and 263 (36.63%) received perioperative chemotherapy; with median OS of 48.20, 46.83, 56.27, and 49.93 months, respectively. No differences in median OS were seen between groups on Kaplan–Meier analysis. No significant difference in Charlson‐Deyo comorbidity status was seen between groups (p = 0.853), while significant difference was seen in maximum tumor size (p = 0.0023). On multivariate analysis, adjuvant (p = 0.010) and perioperative (p = 0.020) chemotherapy were independently associated with OS compared to surgery alone.DiscussionDespite group differences, chemotherapy after surgery was independently associated with improved OS in CLM.
Portal fibroblasts: A renewable source of liver myofibroblasts
O’Hara, Steven P. , LaRusso, Nicholas F.

Mayo Clinic

Hepatology | April 16, 2022 | Volume: 76 | Issue: 5 | Pages: 1240-1242

10.1002/hep.32528 | PMID 35429172 Get It

Reconsidering laboratory‐based anatomy within the backdrop of digital transformation: Bringing an old practice into a new world
Lachman, Nirusha , Pawlina, Wojciech

Mayo Clinic

Anatomical Sciences Education | April 16, 2022 | Volume: 15 | Issue: 3 | Pages: 439-446

10.1002/ase.2182 | PMID 35429369 Get It

A novel WWTR1::AFF2 fusion in an intra‐abdominal soft tissue sarcoma with associated endometriosis
Dashti, Nooshin K. , Dermawan, Josephine K. , Schoolmeester, J. Kenneth , Halling, Kevin C. , Antonescu, Cristina R. , Dermawan, Josephine K T

Mayo Clinic

Genes, Chromosomes and Cancer | April 16, 2022 | Volume: 61 | Issue: 8 | Pages: 497-502

10.1002/gcc.23045 | PMID 35429182 Get It

AbstractApplication of molecular testing in clinical practice has led to significant advances in the classification of soft tissue sarcomas. Despite remarkable progress, there are still challenging cases that remain unclassified. In this study, we present an unusual spindle cell sarcoma arising in the abdominal cavity of a 37‐year‐old female. An extensive panel of immunostains was nonspecific for a line of differentiation and the tumor was subjected to targeted RNA sequencing for further classification. The findings showed a novel WWTR1::AFF2 fusion, which was further confirmed by break‐apart FISH analysis for WWTR1 gene rearrangement. The tumor was attached to the wall of sigmoid colon and showed a highly cellular proliferation of plump spindle to epithelioid cells arranged in intersecting fascicles. Areas of extensive endometriosis were identified adjacent to the tumor. The immunoprofile was significant for reactivity with desmin, calponin, WT‐1, ER, and PR, while negative for CD10, SMA, caldesmon, pan‐keratin, ALK, CD117, and S100. The patient is alive and well after 11 months of follow‐up. The exact histogenesis of this sarcoma remains unclear, however, the presence of adjacent endometriosis and coexpression of WT1/ER/PR raises the possibility of an unusual endometrioid stromal sarcoma, occurring outside the GYN tract. Additional cases are needed to establish the recurrent potential of this fusion event and to better define its pathogenesis and clinical behavior.
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States
Ahn, Joseph , Lauzon, Marie , Luu, Michael , Noureddin, Mazen , Ayoub, Walid S. , Kuo, Alexander , Sundaram, Vinay , Kosari, Kambiz , Nissen, Nicholas N. , Hendifar, Andrew , Roberts, Lewis R. , Yang, Ju Dong , Ahn, Joseph C , Singal, Amit , Yang, Ju Dong , Roberts, Lewis R , Gong, Jun , Abou‐Alfa, Ghassan K. , Singal, Amit G.

Mayo Clinic

Hepatology | April 16, 2022 | Volume: 76 | Issue: 6 | Pages: 1649-1659

10.1002/hep.32527 | PMID 35429171 Get It

Abstract Background and Aims Immunotherapy has emerged as an effective treatment for patients with advanced‐stage HCC. We aimed to investigate the efficacy of immunotherapy for advanced HCC in a nationwide cohort and racial and ethnic disparities in access to immunotherapy. Approach and Results We used the US National Cancer Database to identify patients with tumor‐node‐metastasis stage 3 or 4 HCC between 2017 and 2018. We performed multivariable Cox regression to identify factors associated with overall survival (OS) and logistic regression to identify factors associated with receipt of immunotherapy. Of the 3,990 patients treated for advanced HCC, 3,248 (81.4%) patients received chemotherapy and 742 (18.6%) patients received immunotherapy as a first‐line treatment. Immunotherapy was associated with improved OS compared with chemotherapy (adjusted HR: 0.76, 95% CI: 0.65–0.88) after adjusting for covariates. There were racial and ethnic disparities in access to immunotherapy, with Hispanic (adjusted OR [aOR]: 0.63, 95% CI: 0.46–0.83) and Black patients (aOR: 0.71, 95% CI: 0.54–0.89) less likely to receive immunotherapy compared with White patients. There was a significant interaction between race‐ethnicity and facility type, with higher disparity observed in nonacademic centers (interaction p = 0.004). Conclusions Immunotherapy was associated with improved OS compared with chemotherapy in advanced HCC. There are significant disparities in early access to immunotherapy, likely due to differential access to clinical trials and experimental therapies. A comprehensive approach to monitoring and eliminating racial‐ethnic disparities in the management of advanced HCC is urgently needed.
Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment
Gertz, Morie A. , Gertz, Morie A

Mayo Clinic

American Journal of Hematology | April 16, 2022 | Volume: 97 | Issue: 6 | Pages: 818-829

10.1002/ajh.26569 | PMID 35429180 Get It

Abstract Disease overview Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues. Clinical features depend on organs involved but can include heart failure with preserved ejection fraction, nephrotic syndrome, hepatic dysfunction, peripheral/autonomic neuropathy, and “atypical smoldering multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS).” Diagnosis Tissue biopsy stained with Congo red demonstrating amyloid deposits with apple‐green birefringence is required for the diagnosis of AL amyloidosis. Invasive organ biopsy is not required in 85% of patients. Verification that amyloid is composed of immunoglobulin light chains is mandatory. The gold standard is laser capture mass spectroscopy. Prognosis N‐terminal pro–brain natriuretic peptide (NT‐proBNP or BNP), serum troponin T (or I), and difference between involved and uninvolved immunoglobulin free light chain values are used to classify patients into four groups of similar size; median survivals are 73, 35, 15, and 5 months. Therapy All patients with a systemic amyloid syndrome require therapy to prevent deposition of amyloid in other organs and prevent progressive organ failure. Current first‐line therapy with the best outcome is daratumumab, bortezomib, cyclophosphamide, and dexamethasone. The goal of therapy is a complete response (CR). In patients failing to achieve this depth of response options for consolidation include pomalidomide, stem cell transplantation, venetoclax, and bendamustine. Future challenges Delayed diagnosis remains a major obstacle to initiating effective therapy prior to the development of end‐stage organ failure. Trials of antibodies to catabolize deposited fibrils are underway.
Safety and effectiveness of radiologic and endoscopic percutaneous gastrostomy placement: A randomized study
Linch, Forrest , Seegmiller, Sara, Mundi, Manpreet S. , Neisen, Melissa , Mohamed Elfadil, Osman , Linch, Forrest B , Seegmiller, Sara L, Hurt, Ryan T. , Mundi, Manpreet S , Neisen, Melissa J, Elfadil, Osman Mohamed

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | April 15, 2022 | Volume: 46 | Issue: 8 | Pages: 1808-1817

10.1002/jpen.2365 | PMID 35428993 Get It

AbstractBackgroundGastrostomy tubes placed radiologically, endoscopically or surgically facilitate long‐term home enteral nutrition (HEN). Patient‐specific clinical factors may affect placement techniques, confounding direct comparisons between radiologically inserted gastrostomy (RIG) and percutaneous endoscopic gastrostomy (PEG) outcomes. This study sought to evaluate the differences in clinical outcomes in patients undergoing gastrostomy tube placement by interventional radiologists or gastroenterologists.MethodsA single‐center prospective trial randomizing patients initiating HEN to RIG or PEG was conducted between March 2018 and June 2021. Patients were followed until the time of gastrostomy removal or until 9 months after tube placement. Tracked complications included peritonitis, abscess, bleeding, bowel perforation, and tube occlusion, malposition, or damage. Periprocedural pain rating and quality of life (QoL) surveys were collected.ResultsForty‐two patients were randomized to RIG or PEG. Twenty patients underwent RIG (mean age, 63.0 ± 11.7 years; 85% male; 95% with head and neck cancer) and 22 patients underwent PEG (mean age, 66.3 ± 10.9 years; 81.8% male; 90.9% with head and neck cancer). RIG and PEG groups had 4.18 ± 5.49 and 2.80 ± 5.82 complications per 1000 HEN days, respectively (P = 0.357). The most frequent complications were tube malposition and abscess formation for the RIG and PEG groups, respectively. No major complications occurred in either group. There was no difference in the average of pain ratings in all pain inventory components across both groups. Both groups reported improvement in overall QoL after gastrostomy tube placement (P = 0.532).ConclusionRIG is noninferior to PEG regarding complication rates, pain, and QoL when compared in a prospective randomized fashion.